Business Context and Reporting Period
Palisade Bio, Inc. (PALI) filed a Form 8-K on May 3, 2024, reporting a material definitive agreement entered into on May 1, 2024. The company, incorporated in Delaware and headquartered in Carlsbad, California, is an emerging growth company trading on the Nasdaq Capital Market.
Key Financial Metrics and Transaction Details
This filing details a private placement offering rather than periodic financial results. Key transaction metrics include:
- Gross Proceeds: Approximately $4.0 million (before fees and expenses).
- Securities Issued: 85,100 shares of Common Stock and 530,142 prefunded warrants.
- Purchase Price: $6.5015 per share or prefunded warrant.
- Additional Warrants: 922,863 warrants issued to the purchaser with an exercise price of $6.314 and a 7-year term.
- Placement Agent Fees: 7.75% cash fee of gross proceeds, up to $75,000 in expense reimbursement, and warrants equal to 6% of the aggregate shares and prefunded warrants sold.
Material Changes Versus Prior Period
The filing does not provide comparative financial data (revenue, profit, or cash flow) against prior periods. The material change is the execution of the securities purchase agreement, which will increase the company's cash liquidity upon closing, expected on or about May 6, 2024.
Guidance, Outlook, and Risks
Outlook and Terms: The company agreed to file a registration statement on Form S-3 within 10 days of closing to allow for the resale of the securities. The prefunded warrants are exercisable immediately at $0.0001 per share, while the standard warrants have a 7-year term.
Risks and Contingencies: The transaction is subject to customary closing conditions. The filing includes standard disclaimers that representations and warranties in the purchase agreement are for risk allocation between parties and may not reflect current facts or materiality standards for general stockholders.
Investor Verification Checklist
- Confirm the closing date of the offering (expected May 6, 2024) and the actual net proceeds received after deducting the 7.75% placement fee and expenses.
- Verify the dilution impact of the 85,100 new shares, 530,142 prefunded warrants, and 922,863 standard warrants on existing shareholders.
- Monitor the filing of the Form S-3 registration statement within the required 10-day post-closing window.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.01) for specific covenants or restrictions not summarized in the 8-K.